What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Portfolio Pulse from Benzinga Insights
In the last 3 months, 9 analysts have offered 12-month price targets for Biomarin Pharmaceutical (NASDAQ:BMRN), with an average price target of $107.22, down 4.69% from the previous average of $112.50.
June 14, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biomarin Pharmaceutical's average 12-month price target from 9 analysts is $107.22, a 4.69% decrease from the previous average of $112.50.
The average 12-month price target for Biomarin Pharmaceutical has decreased by 4.69% from the previous average, indicating a mixed sentiment among analysts. While the stock has both bullish and bearish ratings, the overall impact on the stock price in the short term is neutral as the change in the average price target is not significant enough to cause a strong price movement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100